Lundbeck has presented new clinical data on eptinezumab at the 2025 International Headache Congress in São Paulo, highlighting its long-term preventive effectiveness in patients severely affected by chronic migraine.
The company shared six presentations, including three oral sessions on eptinezumab and Lu AG09222. Key findings came from the open-label extensions of the RESOLUTION and SUNSET trials.
In the phase 4 RESOLUTION trial, patients with chronic migraine and medication overuse headache showed sustained reductions in monthly migraine days (MMDs). Around 50% achieved a ≥50% reduction from baseline, with an average decrease of nine MMDs over 12 weeks.
The SUNSET trial, a 60-week extension of the SUNRISE study in Japanese patients, confirmed long-term efficacy. By weeks 49–60, 35.7% of participants achieved a 50% reduction in MMDs, with a rising trend in ≥75% response rates.
Eptinezumab was well tolerated across both trials, with safety profiles consistent with previous studies and existing prescribing information in the US and EU. No new safety signals were reported.
Dr Johan Luthman, EVP and Head of Research & Development at Lundbeck, said: “Patients deserve preventive treatments that not only deliver early relief but sustain their impact over time. The RESOLUTION and SUNSET trials show that patients who experience an early, clinically significant response with eptinezumab continue to maintain this response long-term.”
These findings reinforce Lundbeck’s commitment to improving outcomes for those living with migraine and support the role of eptinezumab as a durable treatment option for chronic sufferers
